WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes – Business Wire (press release)
|
WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes
Business Wire (press release) BALTIMORE–(BUSINESS WIRE)–WindMIL Therapeutics, a clinical stage company developing Marrow-Infiltrating Lymphocytes (MILs™) for cancer immunotherapy, today presented its novel approach to harnessing a patient's immune system to treat solid … |
